BST-CarGel®

Not yet approved by Health Canada, the FDA or the European authorities

BST-CarGel® is aimed at treating focalized cartilage lesions, either from trauma (sports injury or accident) or from secondary osteoarthritis (OA) degeneration.

Arthroscopic view of a cartlage lesion

The various surgical techniques (microfactures, mosaicplasty, autologous chondrocyte implantation) currently used all have their drawbacks including complicated or multiple surgeries, high cost and/or poor outcomes.

Orthopedic surgeons perform 1.6 million of knee arthroscopic procedures each year in the USA. Cartilage lesions are found in a large number of these procedures.

Additionally, a number of patients too young for arthroplasty, suffering from secondary osteoarthritic focal lesions due to previous trauma, body weight, mis-alignment of the joint or from a previous meniscal surgery, may be good candidates for BST-CarGel®. Osteoarthritis affects around 10% of the population. In the USA alone, it represents 21 million people, out of whom around 65% suffer from OA of the knee.

Cartilage lesions in other joints such as the hip, ankle and the shoulder could potentially benefit from BST-CarGel®.

BST-CarGel® will be more cost-effective than the overly-expensive cell-based therapies to address the challenges of the various healthcare systems around the world

BST-InPod™

Not yet approved by Health Canada, the FDA or the European authorities

“Heel pain is a complaint voiced by 14 percent of the adult population and [the American College of Foot and Ankle Surgeons] suspects that millions more silently cope with it”.

It is estimated that 103 million adults complain of heel pain in the USA, Europe and Canada. Current approaches include disposable in-sole products (around $10/unit) or orthotics which cost around US$400 for a period of approximately 2 ½ years. It is estimated that the current market for in-sole products and orthotics could be more than US$ 1 billion for these 3 key markets.

BST-DermOn™

Not yet approved by Health Canada, the FDA or the European authorities

It is estimated that approximately 3.7 million patients in the US currently suffer from chronic wounds, which include pressure ulcers (1.7 million), diabetic foot ulcers (1 million) and venous leg ulcers (1 million).

These wounds are particularly difficult to heal, impair the patient’s quality of life and can lead to serious complications, such as amputations.

It is estimated that 82,000 amputations are performed every year in diabetic patients in the US, each procedure costing around US$25,000.

Current treatments include advanced wound dressings, growth factor gels (Regranex) or bioengineered tissue products (Dermagraft or Apligraf).

The care of such chronic wounds is estimated to be over $1 billion dollars a year in the US.